Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | CFD | P00746 | 3/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 3/20 | 0.33 |
| ▸ | CMA1 | P23946 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625003 | 0.88 | METTL3 (0.41) | METTL3SLC6A4CFDCMA1NOTUM | |
| SCHEMBL3626656 | 0.86 | METTL3 (0.40) | METTL3CFDSLC16A3SLC16A1MCTS1 | |
| SCHEMBL3620073 | 0.86 | METTL3 (0.38) | METTL3CFDP2RX7 | |
| SCHEMBL3628451 | 0.85 | METTL3 (0.42) | METTL3CFDCMA1NOTUMP2RX7 | |
| SCHEMBL3624060 | 0.83 | P2RX7 (0.39) | METTL3CFDCMA1NOTUMP2RX7 | |
| SCHEMBL3618515 | 0.83 | METTL3 (0.44) | METTL3CFDCMA1NOTUM | |
| SCHEMBL3623481 | 0.83 | METTL3 (0.41) | METTL3SLC6A4CFDCMA1NOTUM | |
| SCHEMBL3624155 | 0.83 | METTL3 (0.42) | METTL3CFDCMA1NOTUM | |
| SCHEMBL3623800 | 0.82 | METTL3 (0.41) | METTL3CFDCMA1NOTUMP2RX7 | |
| SCHEMBL3625761 | 0.82 | METTL3 (0.40) | METTL3CFDCMA1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | claimed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | claimed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | METTL3 3971/4885HTR2C 3673/4885SLC6A4 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.